Kit Check®’s Bluesight® for Controlled Substances is Announced as Best in KLAS for Drug Diversion Monitoring in 2021 Best in KLAS Report

For the second year running, Bluesight for Controlled Substances takes top marks in all product categories and receives a score of 90 out of 100

WASHINGTON--(BUSINESS WIRE)--Kit Check, the leading automation vendor in Medication Intelligence solutions that brings cost savings, efficiency, and patient safety to hospitals, today announced its Bluesight for Controlled Substances product won Best in KLAS for Drug Diversion Monitoring in the 2021 Best in KLAS Report. Created by industry-leading healthcare technology analyst firm KLAS Research, the Best in KLAS report celebrates technology solutions that stand out from the competition in various categories.

“We are delighted to win Best in KLAS for Drug Diversion Monitoring for the second year in a row,” said Kevin MacDonald, CEO and Co-Founder of Kit Check. “Our growing community of Bluesight for Controlled Substances customers is helping combat the opioid epidemic in real-time. Sadly, the COVID-19 pandemic has only exacerbated the opioid epidemic with overdose deaths increasing to all-time high levels. We are humbled and proud to have Bluesight for Controlled Substances celebrated in the marketplace during a trying and difficult year for healthcare workers everywhere. It is wonderful to know Bluesight for Controlled Substances hospital users all over the country were comforted in 2020 knowing they can prevent drug diversion and assist struggling team members in getting the help they need.”

KLAS President Adam Gale provides some background on the Best in KLAS award. “Each year, thousands of healthcare professionals across the globe take the time to share their voice with KLAS. They know that sharing their perspective helps vendors to improve and helps their peers make better decisions. These conversations are a constant reminder to me of how necessary accurate, honest, and impartial reporting is in the healthcare industry. The Best in KLAS report and the awards it contains set the standard of excellence for software and services firms. Vendors who win the title of 'Best in KLAS' should celebrate and remember that providers now accept only the best from their products and services. The Best in KLAS award serves as a signal to provider and payer organizations that they should expect excellence from the winning vendors.”

For the report, 39 Bluesight for Controlled Substances users were interviewed about their experience with the product, a larger sample size than any other evaluated vendor. The feedback highlighted Bluesight for Controlled Substances’ industry-leading features. Providers commented that Bluesight for Controlled Substances performed hours and hours of manual audits and data analysis automatically, provided a framework for cohesive collaboration between nursing and pharmacy, and, most importantly, clearly identified providers with anomalous behavior patterns at a higher risk of diverting medications, without creating extraneous data points to sift through. Kit Check’s comprehensive product support and implementation services were also celebrated in provider feedback.

One director of pharmacy highlighted Bluesight for Controlled Substances’ Investigation Portfolios feature that creates a repeatable and robust cross-departmental investigation framework when suspected diversion arises. “The fact that Kit Check[’s Bluesight for Controlled Substances] actually has an investigation workflow sets them apart from other vendors. The solution is organized well with checklists and workflows that we can build into it. Their functionality is far above the functionality of any other vendors’ products we have seen.”

Additionally, one manager highlighted the industry-leading support and feature collaboration Bluesight for Controlled Substances users can expect from Kit Check, especially during the COVID-19 pandemic when providers continue to be stretched thin and risk for diversion only increases. “The vendor is ahead of the curve in terms of integration. We are able to add new drugs frequently. During the COVID-19 crisis, the vendor was instrumental by adding drugs to the system because we saw a huge diversion in our sister hospital. The vendor is able to pivot really quickly and integrate things into the system without making a big push for us.”

The full 2021 Best in KLAS report is available here: https://klasresearch.com/report/best-in-klas-2021/1820.

The 2021 Best in KLAS segment for Drug Diversion Monitoring is available here: https://klasresearch.com/best-in-klas-ranking/drug-diversion-monitoring/2021/365.

To learn more about Kit Check’s solutions, please visit www.kitcheck.com.

To learn more about KLAS, please visit http://www.klasresearch.com.

About Kit Check

Kit Check® is the leading provider of automated medication tracking and diversion detection solutions for hospital pharmacies in the U.S., bringing visibility, simplicity, and predictability to the complex world of medication supply management. Our groundbreaking Medication Intelligence™ solutions provide item level visibility, workflow simplicity and actionable analytics, empowering stakeholders to deliver the right medicine to the right patient at the right time, every time. To date, our more than 700 U.S. and Canadian hospital partners have adopted Kit Check solutions to solve the most challenging of healthcare problems. Kit Check Solutions help providers, save time management inventory, prevent diversion at their facilities, save money on medication spend, and ensure patient safety. More information about Kit Check and our software solutions can be found at kitcheck.com.

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider’s voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance.